Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono Pharmacare's Total Assets for the quarter that ended in Sep. 2025 was ₹1,193 Mil.
During the past 12 months, Mono Pharmacare's average Total Assets Growth Rate was 18.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 97.80% per year.
During the past 5 years, Mono Pharmacare's highest 3-Year average Total Assets Growth Rate was 97.80%. The lowest was 94.00%. And the median was 95.90%.
Note:
The Net Income data used here is two times the semi-annual (Sep. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Mono Pharmacare's Asset Turnover for the quarter that ended in Sep. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Mono Pharmacare Total Assets Related Terms
Mono Pharmacare Total Assets Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Mono Pharmacare's Total Assets for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Total Assets of ₹1,193 Mil as of Sep. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Mono Pharmacare and its competitors.
Is Mono Pharmacare's Total Assets too high?
Mono Pharmacare's current Total Assets is ₹1,193 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Total Assets compare to competitors?
Mono Pharmacare's Total Assets of ₹1,193 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Healthcare Providers & Services company?
A good Total Assets depends on the Healthcare Providers & Services industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Total Assets is ₹1,193 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Total Assets of ₹1,193 Mil. The current Total Assets is ₹1,193 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Total Assets is ₹1,193 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
